| 1. |
|
|
| 2. |
|
|
| 3. |
- Gerotziafas, GT, et al.
(författare)
-
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
- 2020
-
Ingår i: Thrombosis and haemostasis. - : Georg Thieme Verlag KG. - 2567-689X .- 0340-6245. ; 120:12, s. 1597-1628
-
Tidskriftsartikel (refereegranskat)abstract
- COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
|
|
| 4. |
- Frank, U, et al.
(författare)
-
ESVM Guideline on peripheral arterial disease
- 2019
-
Ingår i: VASA. Zeitschrift fur Gefasskrankheiten. - : Hogrefe Publishing Group. - 0301-1526. ; 48:Suppl 102, s. 7-79
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
|
|
| 6. |
- Brorson, Håkan, et al.
(författare)
-
Circumferential suction-asssisted lipectomy is the only surgical procedure that can normalize large chronic fat-transformed lymphedemas
- 2018
-
Ingår i: European Book of Angiology/Vascular Medicine. - 9788825510522 ; , s. 1011-1012
-
Bokkapitel (refereegranskat)abstract
- 2.Brorson H. Circumferential suction-asssisted lipectomy is the only surgical procedure that can normalize large chronic fat-transformed lymphedemas. In: Catalano M, Pecsvarady Z, Olinic D, Wautrecht J-C, Gerotziafas G, Amann-Vesti B, Karetova D, Fagrell B, Diehm C, Kozak M, Edmonds M, editors, European Book of Angiology/Vascular Medicine. Milano, Italy: VAS, UNIMI-H Sacco; 2016. Pp XXX-XXX.
|
|
| 7. |
|
|
